Plain-English translation of NCT06071286 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether analyzing circulating tumor DNA (ctDNA) — tiny pieces of cancer DNA found in the bloodstream — can detect ovarian cancer recurrence earlier than standard methods like imaging and CA-125 blood tests. Researchers will collect blood samples from ovarian cancer patients at different time points during their follow-up care to see if this new blood test can catch cancer coming back before it shows up on scans or causes symptoms.
Over 70% of women with advanced ovarian cancer experience a return of their disease within two years, but current monitoring methods often detect recurrence too late for the most effective treatment. This trial exists to find a more reliable way to catch cancer recurrence as early as possible, so doctors can act faster and potentially improve outcomes.
You likely qualify if…
You likely don't qualify if…
You will have blood samples drawn at several different time points during your regular follow-up visits for ovarian cancer treatment and monitoring. These blood draws are in addition to your standard care and will be analyzed to detect circulating tumor DNA and track how your disease evolves over time. The study involves no special procedures or medications — just routine blood samples that researchers will use to test whether this new blood test can detect recurrence earlier than conventional methods.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy